Valneva SE - American Depositary Shares (VALN)

In our clinical research group, the focus remains squarely on the timeline for Valneva's Lyme disease vaccine candidate. With Pfizer remaining optimistic and regulatory decisions anticipated over the next twelve months alongside the EMA's validation of the Marketing Authorization Application, the clinical narrative is shifting. However, we are carefully watching how management mitigates the fallout from lower-than-expected travel market uptake for IXCHIQ, which recently forced a €4.5 million inventory impairment and significant restructuring charges.

On our desk, the valuation shift after the VALOR readout has completely changed how we approach VALN. Trading near a $676 million market cap with a cash position of €121.5 million, the stock behaves more like an asymmetric, de-risked royalty and milestone play. Despite a messy Q2 featuring a wider net loss and compressed gross margins down to 4.6%, the reiterated full-year product sales guidance of €135 to €150 million and upcoming H2 catalysts give tactical longs a defined risk structure if paired with a disciplined stop.

Analyzing the Q2 2026 financials from a technical auditing perspective, the headline numbers look alarming at first glance—revenues down 33% year-over-year to €65.8 million and a net loss expanding to €63.3 million. However, analysts point out that much of this is tied to one-off factors, including €9.7 million in external manufacturing termination provisions for IXCHIQ and the planned wind-down of third-party distribution. The critical execution metric for the second half will be whether gross margins can successfully rebound past 50% as predicted.